Results 181 to 190 of about 3,492,883 (216)

Targeting non-canonical autophagy overcomes erlotinib resistance in tongue cancer

Tumor Biology, 2016
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) frequently occurs in many human cancers and hampers their therapeutic use. A large body of evidence has demonstrated the pro-survival role of autophagy in many human cancers.
Keqiang, Huang, Dongxu, Liu
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers.

Cancer Letters, 2020
First-generation EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib have significant activity in NSCLC patients with activating EGFR mutations. However, EGFR-TKI resistance inevitably occurs after approximately 12 months of treatment.
Chen Chen, Weiran Liu, Bin Zhang, Liangjiao Zhang, Chenguang Li, Chang Liu, Hua Zhang, Yansong Huo, Yu-Chen Ma, Pengfei Tian, Qi Qi, Jing-Jing Li, Zhe Tang, Zhenfa Zhang, G. Giaccone, D. Yue, Chang-Li Wang   +16 more
semanticscholar   +1 more source

Expression of cyclin D3 confers resistance to erlotinib

Journal of Clinical Oncology, 2007
18054 Background: Transcriptional repression of cyclin D1 occurs during responses to erlotinib (E) both in vitro and in vivo. Cyclin D3 has overlapping function with cyclin D1 but has distinct transcriptional regulation. Methods: The expression of cyclin D3 was compared in E sensitive cell lines (H358, H441) and an E resistant cell line (A549 ...
W. J. Petty, W. R. Voelzke, V. A. Memoli, K. H. Dragnev, J. J. Urbanic, J. R. Rigas, E. Dmitrovsky   +6 more
openaire   +1 more source

Abstract 726: Erlotinib overcomes acquired resistance to cetuximab

Cancer Research, 2011
Abstract The epidermal growth factor receptor (EGFR) is a ubiquitously expressed receptor tyrosine kinase (RTK) and is recognized as a key mediator of proliferation and progression in many human epithelial tumors. Following more than 20 years of preclinical development, five EGFR inhibitors, two monoclonal antibodies and three small ...
Toni M. Brand, Emily F. Dunn, Mari Iida, Rebecca Myers, Chunrong Li, Deric L. Wheeler   +5 more
openaire   +1 more source

Use of erlotinib and thalidomide in advanced NSCLC patients with acquired resistance to erlotinib: A pilot study

Pathology Research and Practice, 2018
Evidences suggested that combined blockade of the VEGF and EGFR pathways can improve the treatment efficacy of non-small-cell lung cancer (NSCLC). In our previously clinical practice, we observed that thalidomide, a potent VEGF inhibitor, can significantly decrease the tumor size of one EGFR-TKI resistance patient with lung cancer cachexia.
Gen-He, Wang, Peng-Fei, Wu, Long-Hui, Zhang, Ping, Fang, Yong, Chen, Gang, Zuo, Yi-Qing, Wu, Shu-Hong, Wang, Guo-Ping, Sun   +8 more
exaly   +3 more sources

Overcoming erlotinib resistance with STAT3 inhibition in pancreatic cancer.

Journal of Clinical Oncology, 2017
304 Background: Pancreatic ductal adenocarcinoma (PDAC) remains a major therapeutic challenge. Cytotoxic chemotherapy remains the standard approach in PDAC, but results in minimal survival benefit for patients, highlighting a desperate need for novel treatment strategies. Epidermal growth factor receptor (EGFR) is overexpressed in 25-90% of PDACs and
Matthew P. Salzberg, N. Merchant
semanticscholar   +2 more sources

RP11-874 J12.4 promotes erlotinib resistance in non-small cell lung cancer via increasing AXL expression.

Life Science
EGFR tyrosine kinase inhibitor (TKI) resistance is a major challenge for EGFR-mutant non-small cell lung cancer (NSCLC) treatment. Our previous work revealed that overexpression of AXL promoted EGFR-TKI resistance through epithelial-mesenchymal ...
Shaobo Huang, Jinling Zhang, Xiaoliang Wu, Baoxia Liang, Nengzhi Pang, Lili Yang, Zhenfeng Zhang   +6 more
semanticscholar   +1 more source

Characterising acquired resistance to erlotinib in non-small cell lung cancer patients

Expert Review of Respiratory Medicine, 2019
Introduction: The therapy of patients with lung adenocarcinoma has significantly changed after the discovery of epidermal growth factor receptor (EGFR) mutations. EGFR mutations occur in 10-15% of Caucasian lung cancer patients and are associated with favorable outcome to orally administered EGFR tyrosine kinase inhibitors (TKIs), like erlotinib ...
Niki Karachaliou, Jillian Wilhelmina Paulina Bracht, Masaoki Ito   +2 more
exaly   +3 more sources

Glioblastoma Multiforme: Molecular Basis of Resistance to Erlotinib

2010
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, exerts widely variable antiproliferative effects on human glioblastoma multiforme (GBM) cell lines in vitro and in vivo. Those effects are independent of EGFR baseline expression levels, raising the possibility that more complex genetic properties form the molecular basis ...
Marc-Eric Halatsch, Georg Karpel-Massler
openaire   +1 more source

Predicting erlotinib resistance in EGFR wild type NSCLC patients.

Journal of Clinical Oncology, 2013
e22065 Background: Cancer patients with wild type EGFR respond to treatment with erlotinib at a lower rate than patients with EGFR mutations. It would be relevant to predict which EGFR wild type patients benefit from erlotinib. We have developed a response predictor based on NCI60 cancer cell lines measurements of erlotinib effect and gene expression
Peter Buhl Jensen, Steen Knudsen, Anker Hansen, Thomas Jensen, Jon Askaa   +4 more
openaire   +1 more source